Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 12, 2025

InVivoPlus anti-mouse OX40 (CD134)

RRID:AB_1107592
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0031, RRID:AB_1107592)

Antibody Information

URL: http://antibodyregistry.org/AB_1107592

Proper Citation: (Bio X Cell Cat# BE0031, RRID:AB_1107592)

Target Antigen: OX40 (CD134)

Host Organism: rat

Clonality: monoclonal

Comments: Applications: in vivo OX40 activation, in vitro OX40 activation
Consolidation on 12/2021: AB_1107592, AB_2894789.

Antibody Name: InVivoPlus anti-mouse OX40 (CD134)

Description: This monoclonal targets OX40 (CD134)

Target Organism: mouse

Clone ID: clone OX-86

Antibody ID: AB_1107592

Vendor: Bio X Cell

Catalog Number: BE0031

Alternative Catalog Numbers: BP0031-5MG, BE0031-1MG, BE0031-5MG, BE0031-25MG, BP0031-50MG, BE0031-100MG, BP0031-100MG, BE0031-50MG, BP0031-25MG

Record Creation Time: 20231110T031700+0000

Record Last Update: 20240725T000741+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse OX40 (CD134).

No alerts have been found for InVivoPlus anti-mouse OX40 (CD134).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Andreata F, et al. (2024) Therapeutic potential of co-signaling receptor modulation in hepatitis B. Cell, 187(15), 4078.

Hirschhorn D, et al. (2023) T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell, 186(7), 1432.

Liu X, et al. (2023) Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer cell, 41(6), 1073.

Pichler AC, et al. (2023) TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation. Immunity, 56(7), 1631.

Cortellino S, et al. (2022) Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. Cell reports, 40(8), 111256.

Ozga AJ, et al. (2022) CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection. Immunity, 55(1), 82.

Agliano F, et al. (2022) Evaluating the glycolytic potential of mouse costimulated effector CD8+ T cells ex vivo. STAR protocols, 3(2), 101441.

Agliano F, et al. (2022) Nicotinamide breaks effector CD8 T cell responses by targeting mTOR signaling. iScience, 25(3), 103932.

Uzhachenko RV, et al. (2021) Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell reports, 35(1),

108944.

Hinterbrandner M, et al. (2021) Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. JCI insight, 6(23).

Monteiro de Oliveira Novaes JA, et al. (2021) Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer prevention research (Philadelphia, Pa.), 14(3), 313.

Weulersse M, et al. (2020) Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity, 53(4), 824.

Morales Del Valle C, et al. (2019) Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism. Cell reports, 27(5), 1434.